TSToshiyuki Sakurai

Toshiyuki Sakurai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Toshiyuki Sakurai has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Masayuki Saruta

    Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

    5 shared publications
  • Atsushi Yoshida

    Center for Gastroenterology and Inflammatory Bowel Disease Ofuna Chuo Hospital Kamakura Japan

    2 shared publications
  • Hiromichi Shimizu

    Department of Gastroenterology and Hepatology Institute of Science Tokyo Bunkyo‐ku, Tokyo Japan

    2 shared publications
  • Kaoru Yokoyama

    Department of Gastroenterology Kitasato University School of Medicine Kanagawa Japan

    2 shared publications
  • Kei Nomura

    Department of Gastroenterology Juntendo University school of Medicine Tokyo Japan

    2 shared publications
  • Kiichiro Tsuchiya

    Department of Gastroenterology Institute of Medicine, University of Tsukuba Ibaraki Japan

    2 shared publications

Latest Publications

  • Open Access

    Effectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)

    by Fumihito Hirai, Katsuyoshi Matsuoka, Kenji Watanabe, Ryota Hokari, Taku Kobayashi, Masayuki Saruta, Hiroshi Nakase, Takayuki Yamamoto, Mao Matsubayashi, Ryuichi Okamoto, et al.

    Background: Carotegrast methyl is an oral α4-integrin antagonist used to induce remission in patients with ulcerative colitis with an inadequate response to 5-aminosalicylate (5-ASA). This multicenter, retrospective observational study evaluated the clinical usefulness of carotegrast methyl in real-world practice. Methods: Patients with an inadequate response to 5-ASA who received carotegrast methyl were included. Clinical data were collected during and after treatment for up to 52 weeks. The primary endpoint was the response rate at week 8. The remission rate at week 8, response/remission rate at end of treatment, cumulative response/remission rate, and adverse drug reactions were also assessed. Effectiveness was evaluated using the patient reported outcomes-2 measure (sum of Mayo subscores for stool frequency and rectal bleeding). Results: Data were collected from 196 patients, of whom 180 were evaluable for effectiveness. The PRO-2-defined response and remission rates at week 8 were 57.8% and 43.3%, respectively, and the rates at the end of treatment (median treatment duration: 83.5 days) were 58.9% and 50.0%, respectively. The cumulative PRO-2-defined response/remission rates increased until week 16, followed by a slight further increase. Adverse drug reactions occurred in 31 of 196 patients (15.8%, 43 events), with no serious events. Conclusions: In terms of patient-reported symptom improvement, carotegrast methyl is an effective and well-tolerated treatment for patients with ulcerative colitis who have an inadequate response to 5-ASA. A substantial proportion of patients responded to 8 weeks of treatment. Continued treatment for up to 16 weeks may improve symptoms, even in patients with insufficient response at week 8.

  • Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan

    by Shintaro Akiyama, Hiromichi Shimizu, Akiko Tamura, Kaoru Yokoyama, Toshiyuki Sakurai, Mariko Kobayashi, Makoto Eizuka, Shunichi Yanai, Kei Nomura, Tomoyoshi Shibuya, et al.

    Background: Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan.Aim: To compare the real‐world efficacy and safety of these three JAK inhibitors in UC.Methods: This was a multicentre, retrospective study of patients with UC started on JAK inhibitors. The primary outcome was clinical remission at 10, 26 and 58 weeks, and at the most recent follow‐up. To compare the efficacy and safety among the JAK inhibitors, we created three matched cohorts (upadacitinib vs. filgotinib, tofacitinib vs. filgotinib and upadacitinib vs. tofacitinib) using propensity score matching.Results: We identified 228 upadacitinib‐treated patients (median follow‐up 49 weeks; IQR 25–72), 215 filgotinib‐treated patients (follow‐up 56 weeks; IQR 17–82) and 159 tofacitinib‐treated patients (follow‐up 112 weeks; IQR 10–258). Clinical remission rates for upadacitinib, filgotinib and tofacitinib at the most recent follow‐up were 72.8%, 50.6% and 45.8%, respectively. Over 70% of the patients previously treated with other biologics or JAK inhibitors achieved clinical remission with upadacitinib. On multivariate analysis, the number of previous advanced therapies was inversely associated with the efficacy of filgotinib and tofacitinib. Comparative analysis showed that upadacitinib‐treated patients had higher efficacy and lower risk of discontinuation than patients treated with other JAK inhibitors. However, upadacitinib had a significant risk of acne.Conclusions: Considering the particularly high efficacy of upadacitinib, even in patients with refractory UC, filgotinib or tofacitinib may be considered as an upfront JAK inhibitor before using upadacitinib.


  • Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan

    by Shintaro Akiyama, Kaoru Yokoyama, Soichi Yagi, Shinichiro Shinzaki, Kozo Tsuruta, Shinichiro Yoshioka, Minako Sako, Hiromichi Shimizu, Mariko Kobayashi, Toshiyuki Sakurai, et al.

    Summary: Background and Aims: While filgotinib, an oral Janus kinase (JAK) 1 preferential inhibitor, is approved for moderately to severely active ulcerative colitis (UC), real‐world studies assessing its short‐ and long‐term efficacy and safety are limited.Methods: This is a multicenter, retrospective study of UC patients who started filgotinib between March 2022 and September 2023. The primary outcome was clinical remission, defined as a partial Mayo score ≤1 with a rectal bleeding score of 0, or Simple Clinical Colitis Activity Index (SCCAI) ≤2 with a blood‐in‐stool score of 0. Secondary outcomes included clinical response, corticosteroid‐free remission, and endoscopic improvement. Outcomes were assessed at 10, 26, and 58 weeks based on patients with available follow‐up. Adverse events were evaluated.Results: We identified 238 UC patients and 54% had prior exposure to biologics/JAK inhibitors. The median baseline partial Mayo score and SCCAI were 5 (IQR 3–6) and 4 (IQR 2–7). Clinical remission rates based on per‐protocol analysis at 10, 26, and 58 weeks were 47% (70/149), 55.8% (48/86), and 64.6% (31/48), respectively. At a median follow‐up of 28 weeks (IQR 10–54) with a discontinuation rate of 39%, the rates of clinical remission, clinical response, corticosteroid‐free remission, and endoscopic improvement were 39.9% (81/203), 54.7% (111/203), and 36.5% (74/203), and 43.5% (10/23), respectively. These rates were comparable between biologic/JAK inhibitor‐naïve and ‐experienced patients. While three patients (1.3%) developed herpes zoster infection, no cases of thrombosis or death were reported.Conclusions: Real‐world data demonstrate favourable clinical and safety outcomes of filgotinib for UC.


  • Open Access

    Prostaglandin E‐major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase

    by Toshiyuki Sakurai, Yoshihiro Akita, Haruna Miyashita, Ryosuke Miyazaki, Yuki Maruyama, Tomoko Saito, Mariko Shimada, Takuji Yamasaki, Seiji Arhihiro, Tomohiro Kato, et al.

    Background and Aim: Ulcerative colitis (UC) is usually detected by clinical symptoms, such as bleeding and diarrhea; however, it is rather difficult to assess during asymptomatic clinical remission (CR). Hence, there is a need for a biomarker that can reliably detect UC during remission. We previously reported on the utility of the prostaglandin E‐major urinary metabolite (PGE‐MUM) as a biomarker reflecting UC activity. In this study, we evaluated the effectiveness of the PGE‐MUM in the diagnosis of endoscopic, histological, and histo‐endoscopic mucosal remission of UC, comparing with fecal tests.Methods: This prospective study was conducted at the Jikei University Hospital between August 2017 and January 2021. Patients with UC in CR scheduled to undergo colonoscopy were included. The association between the PGE‐MUM with endoscopic remission (ER), histological remission (HR), and complete mucosal healing (CMH, defined as histo‐endoscopic remission) was analyzed. We also compared the area under the curve (AUC) for the receiver operating characteristic curves between PGE‐MUM, fecal calprotectin (FC), and fecal immunochemical test (FIT).Results: In total, 128 patients were analyzed. PGE‐MUM differed significantly in ER versus non‐ER (14.5 vs 16.7, P = 0.028), HR versus non‐HR (14.2 vs 17.4, P = 0.004), and CMH versus non‐CMH (14.3 vs 16.7, P = 0.021). There were no significant differences between the AUCs for PGE‐MUM, FC, and FIT for ER, HR, or CMH.Conclusions: The PGE‐MUM can determine CMH in UC even during CR, regardless of the disease phenotype, indicating its clinical benefit for non‐invasive monitoring.


  • IT IS SO USEFUL TO KNOW GASTRIC CANCER RISK AT GASTRIC ENTRANCE (CARDIA) WITH THE PRESENCE OF AN EASY SIMPLE SIGN

    by T Yamasaki, Y Kinoshita, Y Akita, H Miyashita, Y Maruyama, R Miyazaki, T Sakurai, M Mitsunaga, M Saruta

    Aims We have confused with various newly endoscopic findings (patchy redness and map-like redness etc.) after H.pylori(HP)eradication. On this time, we have found out a new other ultimate useful finding showing HP related gastritis at gastric cardia including present and post HP infection. Our aim of this study is to elucidate the possibility of judgement with only this cardiac endoscopic view about presence or absence with HP infection. Methods We have found out so useful and specific cardiac image (Whale Shark Sign: WSS) closely related to HP infection six years ago. We have examined the presence of WSS on 5, 423 cases that have been able to overview on their endoscopic profiles. The 4,939 cases their serum HP antibody titers were measured from Jan. 2012 to Oct. 2019. A total of 3,837 patients (HP positive) were enrolled. Results Mean age of patients was 51.2 years old. The positive predictive value (PPV) of WSS was surprisingly high (98.9%). According to this high PPV, we can think WSS positive cases are high risk of gastric cancer. This WSS mean that the presence of irregular gastric mucosal surface pattern and the presence of lymphoid hyperplasia, that showing HP infectious stomach. This lymphoid hyperplasia at gastric cardia were recognized small round whitish nodules on white light endoscopy. And this was more emphasized with image-enhanced endoscopy (Narrow Band Imaging: NBI), it looks like Whale Shark. It is so useful to know gastric cancer risk at gastric entrance (cardia) with the presence of an easy simple sign. This WSS sign is so simple and easy for every gastroenterologist. Conclusions We have been able to judge the presence of HP infection with only cardiac endoscopic image (WSS). Since this sign is very easy and simple, everyone will be able to judge the presence of HP infection and gastric cancer risk.

  • Open Access

    Pulmonary Embolism and Deep Vein Thrombosis Complicating Acute Aortic Dissection during Medical Treatment

    by Satoshi Morimoto, Takehiko Izumi, Toshiyuki Sakurai, Kimiaki Komukai, Makoto Kawai, Hidenori Yagi, Kenichi Hongo, Takahiro Shibata, Seibu Mochizuki

    Acute aortic dissection of Stanford type A with intramural hematoma was diagnosed based on computed tomography (CT) findings in a 60-year-old man. During medical treatment, pulmonary embolism and deep vein thrombosis developed. CT revealed thrombosis in the right pulmonary artery, and 99mTc pulmonary perfusion scintigraphy showed defects in the right lung field. CT showed thrombus in the common iliac vein. An inferior vena caval filter was placed because anticoagulation therapy was contraindicated. A CT scan before discharge showed no thrombus in the pulmonary artery or common iliac vein, but a newly captured thrombus was found inside the filter.